Document Detail

Comparison of the protective effects of ischemic preconditioning and the Na+/H+ exchanger blockade.
MedLine Citation:
PMID:  10935527     Owner:  NLM     Status:  MEDLINE    
The protective effects of ischemic preconditioning (IP) and Na+/H+ exchanger blockade (NHEb) by two blockers [ethylisopropylamiloride (EIPA) and HOE 642] were compared in the isovolumic perfused rat heart. The impairment in systolic and diastolic function detected in control ischemic hearts (C) exposed to 20 min of ischemia and 30 min of reperfusion was diminished in similar extent by IP and by NHEb with EIPA and HOE 642. At the end of the reperfusion period +dP/dtmax values were 57+/-9% in C hearts and 94+/-6%, 82+/-6% and 104+/-6% after IP and NHEb with EIPA and HOE 642, respectively. A depletion of ATP levels detected in C hearts after reperfusion (from 20.2+/-0.8 micromol/g dry weight before ischemia to 6.9+/-0.7 micromol/g dry weight) was partially prevented by both IP and NHEb with EIPA (9.2+/-0.7 micromol/g dry weight and 11.1+/-0.5 micromol/g dry weight, respectively). The ischemic contracture (IC), assessed by the left ventricular end diastolic pressure (LVEDP), observed in C hearts (35+/-4 mmHg) was not decreased by IP (40+/-4 mmHg) but it was prevented by NHEb (18+/-4 mmHg and 10+/-3 mmHg with EIPA and HOE 642, respectively). The ATP levels at the end of the ischemic period were similar in C and IP hearts (4.1+/-0.2 micromol/g dry wt vs. 3.3+/-0.4 micromol/g dry wt) but they were significantly higher after NHEb with HOE 642 (7.0+/-1.0 micromol/g dry wt). PKC inhibition by chelerythrine abolished the protection induced by IP after reperfusion although not the improvement induced by NHEb with EIPA. According to the present results, we can conclude that despite the fact that IP and NHEb are protecting the postischemic function in a similar magnitude, both interventions are different in terms of modifying IC that develops during the ischemic period. IC was prevented by NHEb whereas it was not by IP. Furthermore, IP protection and not that obtained by NHEb is abolished by PKC.
S M Mosca; H E Cingolani
Related Documents :
22314117 - Evaluation and pharmacologic approach to patients with resistant hypertension.
22836387 - Nocturnal medications dosing: does it really make a difference in blood pressure contro...
9671907 - Advantages of continuous hyperpolarized arrest with pinacidil over st. thomas' hospital...
22272897 - Blood pressure control and antihypertensive treatment.
1282977 - Endothelium-dependent forearm vasodilation to acetylcholine but not to substance p is i...
9481977 - Is measurement of end-tidal co2 through a nasal cannula reliable?
Publication Detail:
Type:  Comparative Study; In Vitro; Journal Article    
Journal Detail:
Title:  Naunyn-Schmiedeberg's archives of pharmacology     Volume:  362     ISSN:  0028-1298     ISO Abbreviation:  Naunyn Schmiedebergs Arch. Pharmacol.     Publication Date:  2000 Jul 
Date Detail:
Created Date:  2001-01-08     Completed Date:  2001-01-08     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0326264     Medline TA:  Naunyn Schmiedebergs Arch Pharmacol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  7-13     Citation Subset:  IM    
Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Centro de Investigaciones Cardiovasculares, Universidad Nacional de La Plata, Argentina.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenosine Triphosphate / metabolism
Amiloride / analogs & derivatives,  pharmacology
Anti-Arrhythmia Agents / pharmacology
Blood Pressure / drug effects
Enzyme Inhibitors / pharmacology*
Guanidines / pharmacology
Ischemic Preconditioning, Myocardial*
Myocardial Contraction / drug effects
Myocardium / enzymology,  metabolism
Protein Kinase C / antagonists & inhibitors
Sodium-Hydrogen Antiporter / antagonists & inhibitors*
Sulfones / pharmacology
Ventricular Function, Left
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 0/Enzyme Inhibitors; 0/Guanidines; 0/Sodium-Hydrogen Antiporter; 0/Sulfones; 0/cariporide; 1154-25-2/ethylisopropylamiloride; 2609-46-3/Amiloride; 56-65-5/Adenosine Triphosphate; EC Kinase C

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ramipril increases the protein level of skeletal muscle IRS-1 and alters protein tyrosine phosphatas...
Next Document:  Ca2+ oscillation and c-fos gene expression induced via muscarinic acetylcholine receptor in human T-...